FcRn inhibitors: a novel option for the treatment of myasthenia gravis

Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction. The intervention-mediated clearance of immunoglobulin G (IgG) was shown to be effective in controlling the...

Full description

Saved in:
Bibliographic Details
Published in:Neural regeneration research 2023-08, Vol.18 (8), p.1637-1644
Main Authors: Zhu, Li-Na, Hou, Hai-Man, Wang, Sai, Zhang, Shuang, Wang, Ge-Ge, Guo, Zi-Yan, Wu, Jun
Format: Article
Language:English
Subjects:
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction. The intervention-mediated clearance of immunoglobulin G (IgG) was shown to be effective in controlling the progression of the disease. The neonatal Fc receptor (FcRn) plays a key role in prolonging the serum half-life of IgG. Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter, resulting in decreased levels of IgG, including pathogenic autoantibodies, thereby achieving a therapeutic effect. In this review, we detail the substantial research progress, both basic and clinical, relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.
ISSN:1673-5374
1876-7958
DOI:10.4103/1673-5374.363824